Uremic Pruritus Clinical Trial
Official title:
The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease
The purpose of this study was to confirm the efficacy of NB UVB phototherapy in alleviating uremic pruritus and investigate the association between improvement of pruritus and change of serum parameters, including routine biochemical data, immune profile and dialysis adequacy.
We would conduct a randomized study to evaluate the effect of NB UVB therapy on uremic pruritus. The intensity of pruritus will be evaluated using visual analog scale (VAS) score (0 [no pruritus]-10 most severe pruritus]) and a detailed questionnaire assessing various characteristics of pruritus at baseline . The patients with the intensity of pruritus VAS score more than 5 will be randomized to narrow band UVB and control group. Phototherapy was administered to the whole body surface 2-3 sessions per week for total 18 sessions in a UV irradiation cubicle. The dose increased from 210mJ/cm2 .Doses were increased by 10 % at every session. The control group received time-matched exposures to long-wave ultraviolet light. The investigator will determine the pruritic intensity at baseline every 3 sessions by VAS score and by detailed questionnaire at baseline and after 18 sessions. The blood sample will also be collected at baseline and after treatment to determine factors associated with improvement. ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04728984 -
A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet
|
Phase 3 | |
Completed |
NCT02143973 -
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Terminated |
NCT01660243 -
Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis
|
Phase 2 | |
Completed |
NCT06159686 -
The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05525234 -
A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus
|
Phase 4 | |
Completed |
NCT03002233 -
TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus
|
Phase 1 | |
Completed |
NCT03998163 -
CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
Active, not recruiting |
NCT05885737 -
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
|
Phase 3 | |
Recruiting |
NCT04393675 -
Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
|
Phase 1/Phase 2 | |
Completed |
NCT03576235 -
Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients
|
N/A | |
Completed |
NCT05575193 -
Acupressure on Uremic Pruritus and Sleep Quality Among Patients Receiving Hemodialysis
|
N/A | |
Completed |
NCT02858726 -
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 2/Phase 3 | |
Completed |
NCT02143648 -
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
|
Phase 2/Phase 3 | |
Recruiting |
NCT06446310 -
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
|
Phase 3 | |
Completed |
NCT03758079 -
Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus
|
Phase 4 | |
Completed |
NCT02229929 -
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
|
Phase 2 | |
Completed |
NCT04639674 -
AST-120 in Hemodialysis Patients With Uremic Pruritus
|
Phase 4 | |
Completed |
NCT03636269 -
CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
|
Phase 3 | |
Not yet recruiting |
NCT06466421 -
Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis
|
Phase 4 | |
Completed |
NCT04711603 -
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
|
Phase 3 |